Literature DB >> 27757315

Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Aikaterini Hatzioannou1, Saba Nayar2, Anastasios Gaitanis1, Francesca Barone2, Constantinos Anagnostopoulos1, Panayotis Verginis1.   

Abstract

The beneficial effects of checkpoint blockade in tumor immunotherapy are limited to patients with increased tumor-infiltrating lymphocytes (TILs). Delineation of the regulatory networks that orchestrate the presence of TILs holds great promise for the design of effective immunotherapies. Podoplanin/gp38 (PDPN)-expressing lymph node stromal cells (LNSCs) are present in tumor stroma; however, their effect in the regulation of TILs remains elusive. Herein we demonstrate that intratumor injection of ex-vivo-isolated PDPN+ LNSCs into melanoma-bearing mice induces elimination of TILs and promotes tumor growth. In support, PDPN+ LNSCs exert their function through direct inhibition of CD4+ T cell proliferation in a cell-to-cell contact independent fashion. Mechanistically, we demonstrate that PDPN+ LNSCs mediate T cell growth arrest and induction of apoptosis to activated CD69+CD4+ T cells. Importantly, LTbR-Ig-mediated blockade of PDPN+ LNSCs expansion and function significantly attenuates melanoma tumor growth and enhances the infiltration and proliferation of CD4+ TILs. Overall, our findings decipher a novel role of PDPN-expressing LNSCs in the elimination of CD4+ TILs and propose a new target for tumor immunotherapy.

Entities:  

Keywords:  CD4+ tumor infiltrating lymphocytes; lymph node stroma cells; lymphocytes; melanoma; tumor

Year:  2016        PMID: 27757315      PMCID: PMC5048774          DOI: 10.1080/2162402X.2016.1216289

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  56 in total

Review 1.  New insights into the development of lymphoid tissues.

Authors:  Serge A van de Pavert; Reina E Mebius
Journal:  Nat Rev Immunol       Date:  2010-08-13       Impact factor: 53.106

Review 2.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

3.  Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self.

Authors:  Je-Wook Lee; Mathieu Epardaud; Jing Sun; Jessica E Becker; Alexander C Cheng; Ai-ris Yonekura; Joan K Heath; Shannon J Turley
Journal:  Nat Immunol       Date:  2006-12-31       Impact factor: 25.606

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

6.  Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Authors:  Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

7.  TLS in Tumors: What Lies Within.

Authors:  Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Trends Immunol       Date:  2015-12-17       Impact factor: 16.687

8.  Lymphatic endothelial cells support tumor growth in breast cancer.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Sci Rep       Date:  2014-07-28       Impact factor: 4.379

9.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

Authors:  Nikhil S Joshi; Elliot H Akama-Garren; Yisi Lu; Da-Yae Lee; Gregory P Chang; Amy Li; Michel DuPage; Tuomas Tammela; Natanya R Kerper; Anna F Farago; Rebecca Robbins; Denise M Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Immunity       Date:  2015-09-01       Impact factor: 31.745

10.  Reproducible isolation of lymph node stromal cells reveals site-dependent differences in fibroblastic reticular cells.

Authors:  Anne L Fletcher; Deepali Malhotra; Sophie E Acton; Veronika Lukacs-Kornek; Angelique Bellemare-Pelletier; Mark Curry; Myriam Armant; Shannon J Turley
Journal:  Front Immunol       Date:  2011-09-12       Impact factor: 7.561

View more
  6 in total

1.  Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.

Authors:  Themis Alissafi; Aikaterini Hatzioannou; Konstantinos Mintzas; Roza Maria Barouni; Aggelos Banos; Sundary Sormendi; Alexandros Polyzos; Maria Xilouri; Ben Wielockx; Helen Gogas; Panayotis Verginis
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

Review 2.  Podoplanin in Inflammation and Cancer.

Authors:  Miguel Quintanilla; Lucía Montero-Montero; Jaime Renart; Ester Martín-Villar
Journal:  Int J Mol Sci       Date:  2019-02-06       Impact factor: 5.923

3.  An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion.

Authors:  Aikaterini Hatzioannou; Aggelos Banos; Theodore Sakelaropoulos; Constantinos Fedonidis; Maria-Sophia Vidali; Maren Köhne; Kristian Händler; Louis Boon; Ana Henriques; Vasiliki Koliaraki; Panagiotis Georgiadis; Jerome Zoidakis; Aikaterini Termentzi; Marc Beyer; Triantafyllos Chavakis; Dimitrios Boumpas; Aristotelis Tsirigos; Panayotis Verginis
Journal:  Nat Immunol       Date:  2019-12-16       Impact factor: 25.606

Review 4.  Lymphatics in Tumor Progression and Immunomodulation.

Authors:  Claire Y Li; Stav Brown; Babak J Mehrara; Raghu P Kataru
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 5.  Platelet-activating factor podoplanin: from discovery to drug development.

Authors:  Ai Takemoto; Kenichi Miyata; Naoya Fujita
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

6.  CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis.

Authors:  Joshua H Bourne; Nonantzin Beristain-Covarrubias; Malou Zuidscherwoude; Joana Campos; Ying Di; Evelyn Garlick; Martina Colicchia; Lauren V Terry; Steven G Thomas; Alexander Brill; Jagadeesh Bayry; Steve P Watson; Julie Rayes
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.